trending Market Intelligence /marketintelligence/en/news-insights/trending/tsTmbfgaBSSGxjSIpoOICw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Australia's Exopharm raises A$7M in IPO

Virtual Multichannel Revenues Projected To Soar In Next Five Years

Street Talk Episode 45 - Fed Moving From Rate Hikes To Lower For Longer

Consumer Engagement Remains Challenging For OTT Players In Asia

Cord Cutting, Shaving Hits Smaller Networks Hard


Australia's Exopharm raises A$7M in IPO

Australia's Exopharm Ltd. raised A$7 million in its IPO.

The Melbourne-based developer of regenerative medicines sold 35 million shares at 20 Australian cents apiece. The shares are expected to start trading Dec. 18 on the ASX.

Exopharm said proceeds from the IPO will go toward its development program, which is focused on product candidates Plexaris and Exomeres, which are exosomes derived from human platelets and adult stem cells, respectively.

Exopharm expects to market Plexaris for indications such as wound healing, dry age-related macular degeneration and osteoarthritis. The company is currently testing Plexaris and Exomeres in animal models.